Travere Therapeutics (TVTX) Other Operating Expenses (2011 - 2026)

Travere Therapeutics' Other Operating Expenses history runs 16 years deep, the most recent figure standing at $26.8 million for Q1 2026.

• Quarterly Other Operating Expenses rose 56.49% year-over-year to $26.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.4 million (up 38.68% YoY) and the FY2025 annual result came in at $10.3 million, down 85.83% from the prior year.
• Other Operating Expenses was $26.8 million for Q1 2026 at Travere Therapeutics, up from $2.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $66.7 million in Q1 2024 and bottomed at -$8.0 million in Q1 2022.
• A 5-year average of $7.2 million and a median of $1.6 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses slumped 274.05% — and 2024, when it jumped 1509.38%.
• Travere Therapeutics' Other Operating Expenses stood at $868000.0 in 2022, then jumped by 425.81% to $4.6 million in 2023, then slumped by 43.23% to $2.6 million in 2024, then slipped by 1.47% to $2.6 million in 2025, then jumped by 948.41% to $26.8 million in 2026.
• Business Quant data shows TVTX's Other Operating Expenses at $26.8 million in Q1 2026, $2.6 million in Q4 2025, and $1.6 million in Q3 2025.